144 related articles for article (PubMed ID: 37457220)
21. Disparities in glioblastoma survival by case volume: a nationwide observational study.
Raj R; Seppä K; Luostarinen T; Malila N; Seppälä M; Pitkäniemi J; Korja M
J Neurooncol; 2020 Apr; 147(2):361-370. PubMed ID: 32060840
[TBL] [Abstract][Full Text] [Related]
22. Outcomes and Patterns of Care in Elderly Patients with Glioblastoma Multiforme.
Nunna RS; Khalid SI; Patel S; Sethi A; Behbahani M; Mehta AI; Adogwa O; Byrne RW
World Neurosurg; 2021 May; 149():e1026-e1037. PubMed ID: 33482415
[TBL] [Abstract][Full Text] [Related]
23. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.
Ohgaki H; Kleihues P
J Neuropathol Exp Neurol; 2005 Jun; 64(6):479-89. PubMed ID: 15977639
[TBL] [Abstract][Full Text] [Related]
24. The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries.
Global Retinoblastoma Study Group
Lancet Glob Health; 2022 Aug; 10(8):e1128-e1140. PubMed ID: 35839812
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors of patients with Gliomas - an analysis on 335 patients with Glioblastoma and other forms of Gliomas.
Liang J; Lv X; Lu C; Ye X; Chen X; Fu J; Luo C; Zhao Y
BMC Cancer; 2020 Jan; 20(1):35. PubMed ID: 31941467
[TBL] [Abstract][Full Text] [Related]
26. [Glioblastomas: clinical study and search for prognostic factors].
Mineo JF; Quintin-Roue I; Lucas B; Buburusan V; Besson G
Neurochirurgie; 2002 Dec; 48(6):500-9. PubMed ID: 12595806
[TBL] [Abstract][Full Text] [Related]
27. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma.
Farrell C; Shi W; Bodman A; Olson JJ
J Neurooncol; 2020 Nov; 150(2):269-359. PubMed ID: 33215345
[TBL] [Abstract][Full Text] [Related]
28. Variation in management of spinal gliobastoma multiforme: results from a national cancer registry.
Moinuddin FM; Alvi MA; Kerezoudis P; Wahood W; Meyer J; Lachance DH; Bydon M
J Neurooncol; 2019 Jan; 141(2):441-447. PubMed ID: 30460627
[TBL] [Abstract][Full Text] [Related]
29. Survival times of patients with glioblastoma in low- and middle-income countries: a systematic review and meta-analysis.
Dy LF; Ong EP; Espiritu AI; Spears J; Omar AT
Neurosurg Rev; 2022 Oct; 45(5):3393-3403. PubMed ID: 36044130
[TBL] [Abstract][Full Text] [Related]
30. Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme.
Kim YH; Kim T; Joo JD; Han JH; Kim YJ; Kim IA; Yun CH; Kim CY
Cancer; 2015 Sep; 121(17):2926-32. PubMed ID: 25975354
[TBL] [Abstract][Full Text] [Related]
31. Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution.
Joo JD; Kim H; Kim YH; Han JH; Kim CY
J Korean Med Sci; 2015 Nov; 30(11):1597-603. PubMed ID: 26539003
[TBL] [Abstract][Full Text] [Related]
32. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
33. Glioblastoma management in the temozolomide era: have we improved outcome?
Lwin Z; MacFadden D; Al-Zahrani A; Atenafu E; Miller BA; Sahgal A; Menard C; Laperriere N; Mason WP
J Neurooncol; 2013 Nov; 115(2):303-10. PubMed ID: 23979682
[TBL] [Abstract][Full Text] [Related]
34. Treatment and survival of glioblastoma patients in Denmark: The Danish Neuro-Oncology Registry 2009-2014.
Hansen S; Rasmussen BK; Laursen RJ; Kosteljanetz M; Schultz H; Nørgård BM; Guldberg R; Gradel KO
J Neurooncol; 2018 Sep; 139(2):479-489. PubMed ID: 29754199
[TBL] [Abstract][Full Text] [Related]
35. Treatment at high-volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer.
David JM; Ho AS; Luu M; Yoshida EJ; Kim S; Mita AC; Scher KS; Shiao SL; Tighiouart M; Zumsteg ZS
Cancer; 2017 Oct; 123(20):3933-3942. PubMed ID: 28640546
[TBL] [Abstract][Full Text] [Related]
36. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
Lewitzki V; Klement RJ; Kosmala R; Lisowski D; Flentje M; Polat B
Radiat Oncol; 2019 Dec; 14(1):227. PubMed ID: 31831026
[TBL] [Abstract][Full Text] [Related]
37. [The phenomenon of long-term survival in glioblastoma patients. Part I: the role of clinical and demographic factors and an IDH1 mutation (R 132 H)].
Goryaynov SA; Gol'dberg MF; Golanov AV; Zolotova SV; Shishkina LV; Ryzhova MV; Pitskhelauri DI; Zhukov VY; Usachev DY; Belyaev AY; Kondrashov AV; Shurkhay VA; Potapov AA
Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(3):5-16. PubMed ID: 28665384
[TBL] [Abstract][Full Text] [Related]
38. Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide.
Donato V; Papaleo A; Castrichino A; Banelli E; Giangaspero F; Salvati M; Delfini R
Tumori; 2007; 93(3):248-56. PubMed ID: 17679459
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors in glioblastoma multiforme patients receiving high-dose particle radiotherapy or conventional radiotherapy.
Matsuda M; Yamamoto T; Ishikawa E; Nakai K; Zaboronok A; Takano S; Matsumura A
Br J Radiol; 2011 Dec; 84 Spec No 1(Spec Iss 1):S54-60. PubMed ID: 21427185
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
